Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 5 Brain Neoplasms 2 Triple Negative Breast Neoplasms 1 Solid Tumor, Adult 1 Meningeal Neoplasms 1 Breast Cancer Metastatic 1

Interventions

Fulvestrant 5 dalpiciclib 3 Letrozole 3 ribociclib 2 palbociclib 2 fluzoparib 2 exemestane 2 apatinib 2 Anastrozole 2 trastuzumab deruxtecan 1 sacituzumab govitecan 1 pyrotinib 1 pegfilgrastim 1 patritumab deruxtecan 1 olaparib 1 irinotecan sucrosofate 1 abemaciclib 1 Zoledronic Acid 1 Rogaratinib 1 Patient Reported Outcome Measures 1 Paclitaxel 1 Neoadjuvant Therapy 1 Liposomes 1 Irinotecan 1 Ga(III)-DOTATOC 1 Everolimus 1 Cell Separation 1 Capecitabine 1 Bevacizumab 1 Aromatase Inhibitors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Breast Cancer Metastatic × patritumab deruxtecan × Clear all

NCT06298084 2024-03-29

ICARUSBREAST02

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡